Our Partners
On-demand Translational Imaging & AI/ML-driven data analysis consulting and R&D for CROs, Pharma Partners, and Biotech
On-Demand Translational Imaging Expertise for CROs, Biotechs, and Pharma Partners with 10+ years of experience bridging preclinical models and clinical impact.
Specialized in end-to-end imaging workflows—from ex-vivo, in-vitro, and in vivo disease models to AI powered high field MRI (7 to 21.1T), multimodal image analysis, omics integration, and cloud-based pipelines.
Imaging driven product design and delivering scientifically aligned outcomes tailored to your project goals.
✔️ CONTACT
Dr. Shinho Cho
MRI Scientist & Imaging Consultant
📧 scho@MRIstrategy.com
✔️ Biomarker Discovery & Validation
End-to-end support from target identification through validation to Phase I–III
✔️ CNS Disease Model Preclinical Study Design & Execution
Expertise in designing and running translational studies for neurological drug development
✔️ Imaging Protocol Development (MRI)
GLP-compliant preclinical and clinical MRI sequence/protocol design
✔️ AI/ML-based Image Analysis & Pipeline Automation
From data curation to quantitative endpoint extraction
✔️ Multimodal & Omics Data Integration
Fusion of MRI, PET/SPECT, CT, microscopy, behavioral, and multi-omics datasets
✔️ Cloud-Based Analytics Pipelines Development
Secure, scalable deployments with DICOM interoperability
✔️ Imaging-Driven Product Design
Conceptualization and prototyping of diagnostic devices and software
✔️ Imaging Core Lab & Quantitative Review
Blinded adjudication, QA/QC for centralized readouts
✔️ Regulatory & Compliance Consulting
Guidance for IACUC/IRB, GLP/GMP/FDA/EMA standards
✔️ Scientific Writing & Communication
Grant proposals, regulatory dossiers, manuscripts, and technical presentations
Developed a cloud-native, multimodal imaging-omics pipeline using Flywheel.io to support biomarker discovery in prostate cancer. Integrated MRI and omics datasets at scale, enabling automated data curation and machine learning–driven analysis.
✔️Achieved biomarker identification performance exceeding 50% sensitivity and specificity, supporting translational research applications.
Led translational imaging studies combining deep brain stimulation (DBS) and fMRI in Parkinson’s patients and large-animal models. Designed MRI-guided neurosurgical planning for DBS electrode placement.
✔️Enhanced stimulation-specific network mapping. Improved DBS programming accuracy by 25% and reduced surgical planning time by 40%.
Optimized Bruker MRI protocols across 7-9.4 Tesla systems for TgF344-AD rodents to detect early structural and functional biomarkers of Alzheimer’s disease. Custom-tailored parameters, coil designs, and artifact suppression strategies enhanced SNR and cross-platform reproducibility.
✔️The finalized protocol is used in early-phase biomarker discovery and therapeutic trials.
Performed pharmacodynamic mapping of acute morphine exposure using rodent MRI (9.4 T), identifying CNS alterations. Assessed biodistribution and CNS penetration of Feraheme (iron-based agent) and validated a manganese-based contrast agent with 50% signal enhancement (a.k.a MEMRI).
✔️Demonstrated translational potential for functional imaging in neuropharmacology.
Used diffusion and resting-state MRI to characterize brain-wide alterations in GLT-1 gene-mutant rodents versus wild-type (21.1 Tesla - world's unique MRI). Tractography and connectivity analyses revealed distinct network disruptions linked to astrocytic glutamate transport.
✔️Findings provide foundational imaging-based evidence for gene therapy strategies targeting GLT-1 dysregulation.
I commit to excellence, integrity, and clear communication.
You can expect high-quality results, strict timelines, and trust-based collaboration.
Let’s build something remarkable — together.
Dr. Shinho Cho
MRI Scientist & Imaging Consultant
📧 scho@MRIstrategy.com
🔗 https://www.linkedin.com/in/shinho-cho-ph-d-0573b54b/
https://www.linkedin.com/in/shinho-cho-ph-d-0573b54b/
Tallahassee, FL 32317
Mon-Fri: 9am-5pm
AI Website Software